Extended Data Figure 1 : SOX2–GFP expression in skin hyperplasia.

From: SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma

Extended Data Figure 1

a, b, Genetic strategy (a) and experimental design (b) used to monitor Sox2 expression during skin tumorigenesis. c, Immunostaining for K14 and GFP in the skin epidermis of SOX2–GFP mice treated for 6 weeks with acetone (Ctrl), TPA, DMBA or DMBA/TPA. d, Representative FACS plots of SOX2–GFP expression in the epidermis of mice treated for 6 weeks with acetone (Ctrl), TPA, DMBA or DMBA/TPA. These data show that SOX2–GFP expression is absent in the epidermis of control mice but appears in epidermal hyperplasia during chemical-induced carcinogenesis. e, Immunostaining for K14 and GFP in epidermis from SOX2–GFP knock-in mice treated for 2 weeks with DMSO (Ctrl) or retinoic acid. f, g, Immunostaining for K14 and GFP in epidermal hyperplasia (f) and FACS analysis of the skin epidermis (g) following Kras(G12D) expression and p53 deletion 8 weeks after tamoxifen administration to K14CreER:KrasG12D:p53cKO:SOX2–GFP mice. These data show that SOX2–GFP is expressed in Kras(G12D)-induced epidermal hyperplasia before tumour formation. h, Co-immunostaining for K14 and SOX2–GFP or SOX2 protein in serial sections of SOX2–GFP DMBA/TPA-treated skin. These results show that Sox2 is transcriptionally upregulated in pathological conditions associated with massive and sustained proliferation of epidermal stem cells. However, although SOX2–GFP is detected in skin hyperplasia, SOX2 protein is only detected in skin tumours. Scale bars, 50 μm.